Highlights on Novel Imaging Methods of Pancreatic Cancer

  • Saravanan Kokila Krishnamoorthy Department of Radiology, Columbia University. New York, NY, USA
  • Morris Hayim Department of Radiology, University of Massachusetts Medical Center. Worcester, MA, USA
  • Tyler Vestal Department of Radiology, Columbia University. New York, NY, USA
  • Muhammad Wasif Saif Department of Medicine and Cancer Center, Tufts Medical Center. Boston, MA, USA
Keywords: (18F)-1-alpha-D-(2-deoxy-2-fluoroarabino¬furanosyl)-2-nitroimidazole, Pancreatic Neoplasms, Positron-Emission Tomography, Predictive Value of Tests


Pancreatic cancer is the fourth leading cause of cancer deaths. Since the majority of patients present with incurable metastatic disease, novel imaging methods are needed to identify pancreatic cancer and assess response to therapy. Research presented at the 2013 American Society of Oncology (ASCO) Annual Meeting provided insight into potential imaging methods. We discuss Abstracts #4049, #TPS4144, #TPS4146, and #E15069 in this paper.

Image: Contrast enhanced MRI of pancreatic adenocarcinoma.


Download data is not yet available.

Author Biographies

Saravanan Kokila Krishnamoorthy, Department of Radiology, Columbia University. New York, NY, USA
Assistant Professor of Radiology, Department of Radiology, Columbia University, New York, NY
Morris Hayim, Department of Radiology, University of Massachusetts Medical Center. Worcester, MA, USA
Assistant Professor of Radiology, University of Massachusetts Medical Center, Worcester, MA, USA
Tyler Vestal, Department of Radiology, Columbia University. New York, NY, USA
MD Candidate - Class of 2016, Columbia University, New York, NY, USA


Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.

Muenzel D, Engels HP, Bruegel M, et al. Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. Radiol Oncol. 2012 Mar;46(1):8-18.

Zhao B, Tan Y, Bell DJ, et al. Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. Eur J Radiol. 2013 Jun;82(6):959-68.

Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012 Dec 1;118(23):5749-56.

Uhrig M, Hassel JC, Schlemmer HP, et al. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST. Acad Radiol. 2013 Apr;20(4):423-9.

Nascente CM, Dhani NC, Vines D, Yeung I, Metser U, Serra S, et al. Clinical characterization of hypoxia in pancreatic ductal adenocarcinoma (PDAC) by 18F-FAZA PET and pimonidazole. J Clin Oncol 31, 2013 (Suppl.): Abstract #4049.

Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71(2):270-7.

Vecchiarelli S, Macchini M, Grassi E, Ferroni F, Ciccarese F, Calculli L, et al. Comparing RECIST and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer. J Clin Oncol 31, 2013 (Suppl.): Abstract #e15069.

Schramm N, Englhart E, Schlemmer M, et al. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria. Eur J Radiol. 2013 Jun;82(6):951-8.

Chung WS, Park MS, Shin SJ, et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am J Roentgenol. 2012 Oct;199(4):809-15.

Lee HJ, Kim YT, Kang CH, et al. Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes. Radiology. 2013 Mar 7. [Epub ahead of print].

O'Reilly EM, Lowery MA, Yu KH, Capanu M, Stadler ZK, Epstein AS, et al. Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC). J Clin Oncol 31, 2013 (Suppl.): Abstract #TPS4144.

Yopp AC, Schwartz LH, Kemeny N, et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol. 2011 Aug;18(8):2192-9.

McKinley ET, Smith RA, Zhao P, et al. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med. 2013 Mar;54(3):424-30.

Corroyer-Dulmont A, Pérès EA, Petit E, et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals (18F)-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol. 2013 Jan;15(1):41-56.

Contractor K, Challapalli A, Tomasi G, et al. Imaging of cellular proliferation in liver metastasis by (18F)-fluorothymidine positron emission tomography: effect of therapy. Phys Med Biol. 2012 Jun 7;57(11):3419-33.

Lamarca A, Manoharan P, Asselin MC, Trigonis I, Hindmarsh P, Wood S, et al. Pilot, proof-of-concept studies for determining the feasibility of the use of FLT-PET in patients with pancreatic adenocarcinoma. J Clin Oncol 31, 2013 (Suppl.): Abstract #TPS4146.

Contrast enhanced MRI of pancreatic adenocarcinoma
How to Cite
KrishnamoorthyS., HayimM., VestalT., & SaifM. (2013). Highlights on Novel Imaging Methods of Pancreatic Cancer. JOP. Journal of the Pancreas, 14(4), 388-390. https://doi.org/10.6092/1590-8577/1666
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013

Most read articles by the same author(s)

1 2 > >>